Crizotinib in Patients with Advanced MET Exon 14-Altered NSCLC
Автор: Oncology.TV
Загружено: 2017-07-10
Просмотров: 413
Описание: I'm Alexander Drilon, a thoracic oncologist from Memorial Sloan Kettering Cancer Center, and today we're going to be talking about the activity of crizotinib in MET exon 14 altered non small cell lung cancers. By way of background, MET is a known proto oncogene, and MET Exon 14 encodes a juxtamembrane domain on the receptor that's responsible for receptor degradation.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: